Evidence map›Paper›PMID 42236945›Full record

ArticleNature2026

Centromeric footprints preserve telomere integrity in ALT cancers.

Ragini Bhargava, Megan A Mahlke, Tobias T Schmidt, Christoph Bartenhagen, Baylee A Smith, Katherine L Ramsey, Takoda T Zuehlke, Ray W Bowman, Michelle L Lynskey, Anne R Wondisford and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ragini BhargavaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Megan A Mahlke *Department of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Tobias T Schmidt *The Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9064-6192
Christoph BartenhagenDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, Cologne, Germany.
Baylee A SmithDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0009-0000-6565-5567
Katherine L RamseyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Takoda T ZuehlkeDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Ray W BowmanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Michelle L LynskeyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-0343-3413
Anne R WondisfordDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Jean-Baptiste OuriouDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Sandra Schamus-HayesDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Michael J CalderonDepartment of Cell Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-0820-7888
Simon C WatkinsDepartment of Cell Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0003-4092-1552
April E Williams-WehnerThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-9281-8528
Jennifer M BoneDepartment of Immunology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Alok V JoglekarDepartment of Immunology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-7554-7447
Matthias FischerDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-1363-1242
Jan KarlsederThe Salk Institute for Biological Studies, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7433-9750
Yael Nechemia-ArbelyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. arbelyy@upmc.edu.ORCID http://orcid.org/0000-0001-5753-5485
Roderick J O'SullivanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. osullivanr@upmc.edu.ORCID http://orcid.org/0000-0002-0289-0911

Funding

Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolismR01CA207209 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roderick O'Sullivan · 2016 to 2026
$3.6M
A nucleus-to-mitochondria nucleic acid-sensing pathway prevents bypass of age-associated proliferative boundariesR01AG077324 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Jan Karlseder · 2022 to 2026
$3.0M
Supplement to Promote Diversity: Mechanisms of epigenetic assembly, maintenance and propagation of human centromeresR35GM142717 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NECHEMIA-ARBELY, YAEL · 2021 to 2025
$2.3M
Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cellsR01CA262316 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roderick O'Sullivan · 2022 to 2026
$2.2M
NCI NIH HHS R01 CA207209NCI NIH HHS R01 CA262316NIA NIH HHS R01 AG077324NIGMS NIH HHS R35 GM142717
6 · The paper itself

Abstract

Alternative lengthening of telomeres (ALT) is a specialized telomere extension mechanism associated with 5-10% of all cancers

Indexed as

CentromereNeoplasmsTelomereTelomere HomeostasisAutoantigensCell Line, TumorCentromere Protein ACentromere Protein BChromatinChromosomal Proteins, Non-HistoneDNA-Binding ProteinsDNA MethylationDNA ReplicationDNA, SatelliteEpigenesis, GeneticHumansATRX protein, humanAutoantigensCENPA protein, humanCENPB protein, humanCentromere Protein ACentromere Protein BChromatinChromosomal Proteins, Non-HistoneDNA-Binding ProteinsDNA, SatelliteX-linked Nuclear Protein

Identifiers

PMID42236945
PMCPMC13468120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.